Loading...
XNASOPK
Market cap1.00bUSD
Jan 10, Last price  
1.47USD
1D
-0.68%
1Q
0.68%
Jan 2017
-84.19%
Name

OPKO Health Inc

Chart & Performance

D1W1MN
XNAS:OPK chart
P/E
—
P/S
1.16
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.82%
Rev. gr., 5y
-2.70%
Revenues
863m
-14.01%
000847,0009,440,00013,147,00028,494,00027,979,00047,044,00096,530,00091,100,000491,700,0001,221,700,000966,006,000990,300,000901,900,0001,435,400,0001,774,700,0001,004,200,000863,495,000
Net income
-189m
L-42.42%
-1,926,000-186,000-648,000-268,405,000-39,834,000-30,113,000-18,926,000-1,283,000-29,048,000-114,407,000-171,700,000-30,000,000-25,100,000-305,250,000-153,000,000-312,000,00030,586,000-29,500,000-328,000,000-188,863,000
CFO
-28m
L-70.38%
-1,590,000-897,000-305,000-16,949,000-29,294,000-23,336,000-19,094,000-18,500,000-25,415,000-58,192,000-90,379,000164,024,00032,046,000-92,080,000-109,141,000-172,522,00039,476,00038,337,000-95,189,000-28,197,000
Earnings
Feb 25, 2025

Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
URL
https://www.opko.com/
IPO date
Nov 02, 1995
Employees
4,196
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
863,495
-14.01%
1,004,200
-43.42%
Cost of revenue
634,961
789,900
Unusual Expense (Income)
NOPBT
228,534
214,300
NOPBT Margin
26.47%
21.34%
Operating Taxes
4,437
(63,500)
Tax Rate
1.94%
NOPAT
224,097
277,800
Net income
(188,863)
-42.42%
(328,000)
1,011.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(272)
221,662
BB yield
0.02%
-24.66%
Debt
Debt current
43,116
3,100
Long-term debt
360,685
259,889
Deferred revenue
7
138
Other long-term liabilities
12,199
55,262
Net debt
291,838
81,737
Cash flow
Cash from operating activities
(28,197)
(95,189)
CAPEX
(16,275)
(24,578)
Cash from investing activities
(18,198)
91,038
Cash from financing activities
(11,303)
22,971
FCF
397,709
478,749
Balance
Cash
95,881
153,200
Long term investments
16,082
28,052
Excess cash
68,788
131,042
Stockholders' equity
(2,041,996)
(1,858,433)
Invested Capital
3,769,985
3,683,582
ROIC
6.01%
7.72%
ROCE
12.32%
10.98%
EV
Common stock shares outstanding
751,766
719,061
Price
1.51
20.80%
1.25
-74.01%
Market cap
1,135,167
26.29%
898,826
-71.17%
EV
1,427,005
980,563
EBITDA
333,831
322,955
EV/EBITDA
4.27
3.04
Interest
13,506
12,056
Interest/NOPBT
5.91%
5.63%